FFO
CRVS icon

Fortitude Family Office’s Corvus Pharmaceuticals CRVS Stock Holding History

Fortitude Family Office’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-99
Closed -$1.45K – 2291
2026
Q1 		$1.45K Buy
+99
New +$1.58K ﹤0.01% 1396

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fortitude Family Office's CRVS Position: Q2 2026 in Review

Fortitude Family Office sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 99 shares — an estimated $1.45K sold.

Fortitude Family Office first reported a position in CRVS in Q1 2026 and held it in 1 quarter. The position peaked at $1.45K in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Fortitude Family Office reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 99 Corvus Pharmaceuticals shares in Q2 2026, an estimated $1.45K.
  • Fortitude Family Office first reported a position in Corvus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Fortitude Family Office's Corvus Pharmaceuticals position peaked at $1.45K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.